Seventh Sense Biosystems, Inc.

Seventh Sense Biosystems Receives $3.28 Million Grand Challenges Point-of-Care Diagnostics Grant to Expand Touch Activated Phlebotomy(TM) Technology Platform

Seventh Sense Biosystems Receives $3.28 Million Grand Challenges Point-of-Care Diagnostics Grant to Expand Touch Activated Phlebotomy(TM) Technology Platform

December 16, 2011

CAMBRIDGE, Mass., Dec 16, 2011 (BUSINESS WIRE) -- Seventh Sense Biosystems, Inc., a company developing novel blood sampling technology for decentralized diagnostic testing, announced today that it has been awarded a $3.28 million grant from the Bill & Melinda Gates Foundation. The grant is part of the Grand Challenges in Global Health initiative to seek out innovative ideas for diagnostics in the developing world.

Abbie Celniker - FierceBiotech's 2011 Women in Biotech

Abbie Celniker - FierceBiotech's 2011 Women in Biotech

November 29, 2011

Abbie Celniker has landed back on startup turf at Eleven Biotherapeutics, where she was just named CEO in September. She's now bringing her two decades of experience in biotech drug development to complement the protein engineering hotshots on staff, and all have ambitious goals to advance new protein drugs to treat a slate of diseases such as dry eye. Money helps. So Celniker has also been busy talking to investors and working with the business team on partnering plans.

Click logo to view full article

 

Quanterix Corporation

Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin

Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin

December 1, 2011

CAMBRIDGE, Mass., Dec. 1, 2011 /PRNewswire via COMTEX/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA(TM)) technology, announced today that it has been awarded a one year $250,155 contract from the Department of Homeland Security (DHS) to develop an assay capable of detecting single molecules of botulinum toxin (BoNT) within complex environmental samples.

Receptos, Inc.

Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research

Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research

December 12, 2011

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Receptos Inc. announced today the establishment of a collaboration with Ono Pharmaceutical Co., Ltd. (Osaka, Japan) for the research and development of small molecule modulators of an undisclosed G-protein coupled receptor (GPCR) target. Under the terms of the agreement, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and drive Ono's structure-based drug design efforts.

TARIS Biomedical, Inc.

TARIS™ Initiates Phase 2 Clinical Study with LiRIS® in Interstitial Cystitis Patients

TARIS™ Initiates Phase 2 Clinical Study with LiRIS® in Interstitial Cystitis Patients

November 30, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)-- TARIS Biomedical, Inc., a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 2 clinical study with its novel product candidate, LiRIS®, in patients with Interstitial Cystitis. LiRIS® is designed to continuously deliver lidocaine over an extended period directly to the bladder to relieve symptoms associated with Interstitial Cystitis, such as bladder pain and voiding dysfunction.

Alvine Pharmaceuticals, Inc.

Alvine's ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch by Windhover for a Rare Second Year

Alvine's ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch by Windhover for a Rare Second Year

November 29, 2011

SAN CARLOS, Calif.--(BUSINESS WIRE)--Nov 29, 2011 - Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, announced today that the company's lead therapeutic product candidate for celiac disease, ALV003, has been selected by Windhover and its advisors as one of “The Top 10 Inflammatory/Autoimmune Projects to Watch in 2012.” This is the second year that ALV003 has been named to the Top 10 list.

Mascoma Corporation

Mascoma Awarded $80 Million from the DOE for Construction of Commercial-Scale Hardwood Cellulosic Ethanol Facility in Kinross, Michigan

Mascoma Awarded $80 Million from the DOE for Construction of Commercial-Scale Hardwood Cellulosic Ethanol Facility in Kinross, Michigan

December 14, 2011

Lebanon, New Hampshire – Mascoma Corporation, a renewable fuels company, announced today that it has signed a cooperative agreement with the U.S. Department of Energy (DOE) to assist in the design, construction and operation of a commercial-scale hardwood cellulosic ethanol facility in Kinross, Michigan. The cooperative agreement provides for up to $80 million in DOE funding, in addition to $20 million in funding previously awarded by the DOE related to research and development for this project.

Affinnova, Inc.

Affinnova Delivers a Shot of Innovation for Breathable Foods

Affinnova Delivers a Shot of Innovation for Breathable Foods

December 12, 2011

WALTHAM, Mass., Dec 12, 2011 -- Affinnova, Inc., the global leader in marketing innovation software and services, has helped energize the launch of Breathable Foods' revolutionary new airborne energy shot. When Breathable Foods -- a Cambridge, MA-based creator of inhalable nutrients and sensations -- prepared to introduce its new AeroShot Pure Energy product to the marketplace, the company turned to Affinnova for help in optimizing a product message that would resonate with consumers.

Mascoma Corporation

Mascoma and Valero Establish Joint Venture for Commercial-Scale Hardwood Cellulosic Ethanol Facility in Kinross, Michigan

Mascoma and Valero Establish Joint Venture for Commercial-Scale Hardwood Cellulosic Ethanol Facility in Kinross, Michigan

December 9, 2011

Lebanon, New Hampshire – Mascoma Corporation, a renewable fuels company, announced today that it has entered into definitive agreements with Valero Energy Corporation, the nation’s largest independent oil refiner and a leading ethanol producer, to develop and operate a first-of-its-kind 20 million gallon per year commercial-scale cellulosic ethanol facility in Kinross, Michigan.

Avedro, Inc.

Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking

Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking

December 7, 2011

Avedro, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s VibeX (riboflavin ophthalmic solution) for use with its KXL System (UVA irradiation) for Corneal Cross-linking to treat corneal ectasia following refractive surgery, such as Lasik and photorefractive keratectomy (PRK). Corneal ectasia is a rare outcome of refractive surgery but is a progressive condition that is difficult to manage. This is the company’s second orphan drug designation for VibeX.